In Scrip’s interview with newly-named UroGen Pharma, Ltd. CEO, Liz Barrett, she discusses her decision to leave the top oncology post at Novartis AG to lead UroGen, her plans to see UroGen’s lead asset through the FDA approval and launch processes, and her short- and long-term business development plans for the organization. Tap into Scrip’s insightful interview with this key industry leader for insights into the future of UroGen and its urothelial cancer drug, UGN-101.